{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:12:07Z","timestamp":1793052727442,"version":"4.5.0"},"reference-count":219,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2015,11,24]],"date-time":"2015-11-24T00:00:00Z","timestamp":1448323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009828","name":"Cancer Research Wales","doi-asserted-by":"publisher","award":["506075"],"award-info":[{"award-number":["506075"]}],"id":[{"id":"10.13039\/100009828","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009828","name":"Cancer Research Wales","doi-asserted-by":"publisher","award":["505979"],"award-info":[{"award-number":["505979"]}],"id":[{"id":"10.13039\/100009828","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014332","name":"Life Sciences Research Network Wales","doi-asserted-by":"publisher","award":["508163"],"award-info":[{"award-number":["508163"]}],"id":[{"id":"10.13039\/501100014332","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Adenoviruses (Ad) are commonly used both experimentally and clinically, including oncolytic virotherapy applications. In the clinical area, efficacy is frequently hampered by the high rates of neutralizing immunity, estimated as high as 90% in some populations that promote vector clearance and limit bioavailability for tumor targeting following systemic delivery. Active tumor targeting is also hampered by the ubiquitous nature of the Ad5 receptor, hCAR, as well as the lack of highly tumor-selective targeting ligands and suitable targeting strategies. Furthermore, significant off-target interactions between the viral vector and cellular and proteinaceous components of the bloodstream have been documented that promote uptake into non-target cells and determine dose-limiting toxicities. Novel strategies are therefore needed to overcome the obstacles that prevent efficacious Ad deployment for wider clinical applications. The use of less seroprevalent Ad serotypes, non-human serotypes, capsid pseudotyping, chemical shielding and genetic masking by heterologous peptide incorporation are all potential strategies to achieve efficient vector escape from humoral immune recognition. Conversely, selective vector arming with immunostimulatory agents can be utilized to enhance their oncolytic potential by activation of cancer-specific immune responses against the malignant tissues. This review presents recent advantages and pitfalls occurring in the field of adenoviral oncolytic therapies.<\/jats:p>","DOI":"10.3390\/v7112923","type":"journal-article","created":{"date-parts":[[2015,11,24]],"date-time":"2015-11-24T12:08:12Z","timestamp":1448366892000},"page":"6009-6042","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications"],"prefix":"10.3390","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0549-5677","authenticated-orcid":false,"given":"Hanni","family":"Uusi-Kerttula","sequence":"first","affiliation":[{"name":"Institute of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hulin-Curtis","sequence":"additional","affiliation":[{"name":"Institute of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Davies","sequence":"additional","affiliation":[{"name":"Institute of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-1761","authenticated-orcid":false,"given":"Alan","family":"Parker","sequence":"additional","affiliation":[{"name":"Institute of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2015,11,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.003087-0","article-title":"Adenoviruses: Update on structure and function","volume":"90","author":"Russell","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Robinson, C.M., Singh, G., Lee, J.Y., Dehghan, S., Rajaiya, J., Liu, E.B., Yousuf, M.A., Betensky, R.A., Jones, M.S., and Dyer, D.W. (2013). Molecular evolution of human adenoviruses. Sci. Rep., 3.","DOI":"10.1038\/srep01812"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/CMR.00116-13","article-title":"Adenovirus infections in immunocompetent and immunocompromised patients","volume":"27","author":"Lion","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/43977","article-title":"Virus treatment questioned after gene therapy death","volume":"401","author":"Lehrman","year":"1999","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3181\/00379727-84-20714","article-title":"Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture","volume":"84","author":"Rowe","year":"1953","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/07853890410018934","article-title":"Adenoviruses for treatment of cancer","volume":"37","author":"Kanerva","year":"2005","journal-title":"Ann. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.addr.2011.12.011","article-title":"Evolution of oncolytic adenovirus for cancer treatment","volume":"64","author":"Choi","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMe1205943","article-title":"Tumor immunotherapy directed at PD-1","volume":"366","author":"Ribas","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_10","unstructured":"ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.addr.2005.01.007","article-title":"CAR: A virus receptor within the tight junction","volume":"57","author":"Coyne","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood-2008-09-178459","article-title":"Human erythrocytes bind and inactivate type 5 adenovirus by presenting coxsackie virus-adenovirus receptor and complement receptor 1","volume":"113","author":"Carlisle","year":"2009","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e1000277","DOI":"10.1371\/journal.ppat.1000277","article-title":"The cell adhesion molecule \u201cCAR\u201d And sialic acid on human erythrocytes influence adenovirus in vivo biodistribution","volume":"5","author":"Seiradake","year":"2009","journal-title":"PLoS Pathog."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0092-8674(02)00912-1","article-title":"Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape","volume":"110","author":"Walters","year":"2002","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"12785","DOI":"10.1128\/JVI.01732-07","article-title":"Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob","volume":"81","author":"Wang","year":"2007","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1128\/JVI.74.6.2804-2813.2000","article-title":"Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein","volume":"74","author":"Kirby","year":"2000","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1128\/JVI.78.14.7727-7736.2004","article-title":"Crystal structure of species D adenovirus fiber knobs and their sialic acid binding sites","volume":"78","author":"Burmeister","year":"2004","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10522","DOI":"10.1128\/JVI.00450-10","article-title":"Adenovirus-based vaccines: Comparison of vectors from three species of adenoviridae","volume":"84","author":"Chen","year":"2010","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"10862","DOI":"10.1128\/JVI.00928-12","article-title":"Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys","volume":"86","author":"Li","year":"2012","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nm.2267","article-title":"The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis","volume":"17","author":"Nilsson","year":"2011","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"Waddington","year":"2008","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood-2009-03-208835","article-title":"Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: Effect of mutagenesis on FX interactions and gene transfer","volume":"114","author":"Alba","year":"2009","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3390\/v2102290","article-title":"Tropism-modification strategies for targeted gene delivery using adenoviral vectors","volume":"2","author":"Coughlan","year":"2010","journal-title":"Viruses"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood-2006-04-008532","article-title":"Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes","volume":"108","author":"Parker","year":"2006","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9568","DOI":"10.1128\/JVI.00663-07","article-title":"Targeting of adenovirus serotype 5 (Ad5) and 5\/47 pseudotyped vectors in vivo: Fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5","volume":"81","author":"Waddington","year":"2007","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1128\/JVI.01878-08","article-title":"Effect of neutralizing sera on factor X-mediated adenovirus serotype 5 gene transfer","volume":"83","author":"Parker","year":"2009","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1073\/pnas.0711757105","article-title":"Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo","volume":"105","author":"Kalyuzhniy","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.3107","article-title":"Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement","volume":"19","author":"Xu","year":"2013","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/JVI.05760-11","article-title":"Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors","volume":"86","author":"Khare","year":"2012","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein","volume":"174","author":"Sumida","year":"2005","journal-title":"J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1128\/JVI.78.22.12320-12332.2004","article-title":"Postentry neutralization of adenovirus type 5 by an antihexon antibody","volume":"78","author":"Varghese","year":"2004","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1126\/science.1226625","article-title":"Coagulation factor X activates innate immunity to human species C adenovirus","volume":"338","author":"Doronin","year":"2012","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9610","DOI":"10.1128\/JVI.01070-13","article-title":"Coagulation factor binding orientation and dimerization may influence infectivity of adenovirus-coagulation factor complexes","volume":"87","author":"Irons","year":"2013","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e1004673","DOI":"10.1371\/journal.ppat.1004673","article-title":"Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo","volume":"11","author":"Ma","year":"2015","journal-title":"PLoS Pathog."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/JVI.06254-11","article-title":"Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection","volume":"86","author":"Bradley","year":"2012","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/JVI.06165-11","article-title":"Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions","volume":"86","author":"Bradley","year":"2012","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"15265","DOI":"10.1128\/JVI.79.24.15265-15276.2005","article-title":"Phylogenetic analysis of the main neutralization and hemagglutination determinants of all human adenovirus prototypes as a basis for molecular classification and taxonomy","volume":"79","author":"Madisch","year":"2005","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0969-2126(94)00126-X","article-title":"Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 \u00e5 resolution","volume":"2","author":"Xia","year":"1994","journal-title":"Structure"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7225","DOI":"10.1128\/JVI.77.13.7225-7235.2003","article-title":"Flexibility of the adenovirus fiber is required for efficient receptor interaction","volume":"77","author":"Wu","year":"2003","journal-title":"J. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/sj.mt.6300094","article-title":"Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop","volume":"15","author":"Kritz","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1089\/104303403765255165","article-title":"Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice","volume":"14","author":"Smith","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1099\/vir.0.81889-0","article-title":"Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting","volume":"87","author":"Cascallo","year":"2006","journal-title":"J. Gen. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1128\/JVI.02786-06","article-title":"Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D","volume":"81","author":"Parker","year":"2007","journal-title":"J. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"12249","DOI":"10.1128\/JVI.01584-07","article-title":"Fiber shaft-chimeric adenovirus vectors lacking the KKTK motif efficiently infect liver cells in vivo","volume":"81","author":"Kalyuzhniy","year":"2007","journal-title":"J. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e18205","DOI":"10.1371\/journal.pone.0018205","article-title":"Cell entry and trafficking of human adenovirus bound to blood factor X is determined by the fiber serotype and not hexon: Heparan sulfate interaction","volume":"6","author":"Corjon","year":"2011","journal-title":"PLoS ONE"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/sj.gt.3302875","article-title":"Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector","volume":"14","author":"Myhre","year":"2007","journal-title":"Gene Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/gt.2008.56","article-title":"Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies","volume":"15","author":"Pesonen","year":"2008","journal-title":"Gene Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1128\/jvi.70.4.2116-2123.1996","article-title":"Adenovirus type 5 and 7 capsid chimera: Fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes","volume":"70","author":"Gall","year":"1996","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","article-title":"Integrins \u03b1v\u03b23and \u03b1v\u03b25 promote adenovirus internalization but not virus attachment","volume":"73","author":"Wickham","year":"1993","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0378-1119(88)90389-7","article-title":"Determination of the nucleotide sequence for the penton-base gene of human adenovirus type 5","volume":"69","author":"Neumann","year":"1988","journal-title":"Gene"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.molcel.2004.11.041","article-title":"The structure of the human adenovirus 2 penton","volume":"17","author":"Zubieta","year":"2005","journal-title":"Mol. Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1128\/JVI.77.19.10366-10375.2003","article-title":"Identification of adenovirus (Ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative Ad (Addl1520) for treatment of liver tumors","volume":"77","author":"Hong","year":"2003","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"12322","DOI":"10.1128\/JVI.01608-12","article-title":"Conserved fiber-penton base interaction revealed by nearly atomic resolution cryo-electron microscopy of the structure of adenovirus provides insight into receptor interaction","volume":"86","author":"Cao","year":"2012","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.immuni.2009.04.015","article-title":"Virus binding to a plasma membrane receptor triggers interleukin-1\u03b1-mediated proinflammatory macrophage response in vivo","volume":"31","author":"Miao","year":"2009","journal-title":"Immunity"},{"key":"ref_60","first-page":"163","article-title":"Adenovirus fiber","volume":"199 Pt 1","author":"Chroboczek","year":"1995","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1128\/JVI.79.2.1053-1061.2005","article-title":"Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs","volume":"79","author":"Shayakhmetov","year":"2005","journal-title":"J. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jconrel.2012.05.025","article-title":"Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses","volume":"164","author":"Bradshaw","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2007.10.005","article-title":"Adenovirus vector induced innate immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine applications","volume":"132","author":"Hartman","year":"2008","journal-title":"Virus Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/hum.2014.001","article-title":"Innate immunity to adenovirus","volume":"25","author":"Hendrickx","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1038\/sj.gt.3301611","article-title":"Complement activation by recombinant adenoviruses","volume":"8","author":"Cichon","year":"2001","journal-title":"Gene Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/gt.2008.114","article-title":"Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors","volume":"15","author":"Appledorn","year":"2008","journal-title":"Gene Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1126\/science.286.5447.2156","article-title":"Control of early viral and bacterial distribution and disease by natural antibodies","volume":"286","author":"Ochsenbein","year":"1999","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1182\/blood-2006-06-032524","article-title":"Adenovirus-induced thrombocytopenia: The role of von Willebrand factor and p-selectin in mediating accelerated platelet clearance","volume":"109","author":"Othman","year":"2007","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1006\/mthe.2002.0613","article-title":"In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor","volume":"5","author":"Smith","year":"2002","journal-title":"Mol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1128\/JVI.79.12.7478-7491.2005","article-title":"Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity","volume":"79","author":"Shayakhmetov","year":"2005","journal-title":"J. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1002\/eji.1830251239","article-title":"Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector","volume":"25","author":"Juillard","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/sj.gt.3302037","article-title":"Immunity to adenovirus and adeno-associated viral vectors: Implications for gene therapy","volume":"10","author":"Jooss","year":"2003","journal-title":"Gene Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1099\/vir.0.82685-0","article-title":"Adenovirus vector delivery stimulates natural killer cell recognition","volume":"88","author":"Tomasec","year":"2007","journal-title":"J. Gen. Virol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1128\/JVI.78.6.2666-2673.2004","article-title":"Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors","volume":"78","author":"Sumida","year":"2004","journal-title":"J. Virol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/104303402320138952","article-title":"The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope","volume":"13","author":"Olive","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1099\/vir.0.82867-0","article-title":"The CD4+ T-cell response to adenovirus is focused against conserved residues within the hexon protein","volume":"88","author":"Onion","year":"2007","journal-title":"J. Gen. Virol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/jcp.29.5.411","article-title":"Fluorescent antibody responses to adenoviruses in humans","volume":"29","author":"Ariyawansa","year":"1976","journal-title":"J. Clin. Pathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/(SICI)1096-9071(199611)50:3<230::AID-JMV4>3.0.CO;2-A","article-title":"Seroepidemiology of new AIDS-associated adenoviruses among the San Francisco men\u2019s health study","volume":"50","author":"Schnurr","year":"1996","journal-title":"J. Med. Virol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.1128\/JVI.73.8.6729-6742.1999","article-title":"Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs","volume":"73","author":"Harvey","year":"1999","journal-title":"J. Virol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/gt.2010.1","article-title":"Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses","volume":"17","author":"Sharma","year":"2010","journal-title":"Gene Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1128\/jvi.56.3.896-903.1985","article-title":"Interaction between HeLa cells and adenovirus type 2 virions neutralized by different antisera","volume":"56","author":"Wohlfart","year":"1985","journal-title":"J. Virol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1128\/jvi.62.7.2321-2328.1988","article-title":"Neutralization of adenoviruses: Kinetics, stoichiometry, and mechanisms","volume":"62","author":"Wohlfart","year":"1988","journal-title":"J. Virol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1128\/JVI.72.3.2388-2397.1998","article-title":"Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity","volume":"72","author":"Farace","year":"1998","journal-title":"J. Virol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1128\/JVI.00866-09","article-title":"Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization","volume":"84","author":"Cheng","year":"2010","journal-title":"J. Virol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the STEP study): A double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e1000114","DOI":"10.1371\/journal.ppat.1000114","article-title":"HIV vaccine development in the aftermath of the STEP study: Re-focus on occult HIV infection?","volume":"4","year":"2008","journal-title":"PLoS Pathog."},{"key":"ref_87","first-page":"351","article-title":"Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and The United States","volume":"11","author":"Nwanegbo","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/JCM.01249-06","article-title":"Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa","volume":"44","author":"Thorner","year":"2006","journal-title":"J. Clin. Microbiol."},{"key":"ref_89","unstructured":"National Institute for Heath and Care Excellence Ovarian Cancer: The Recognition and Initial Management of Ovarian Cancer. Available online: http:\/\/www.nice.org.uk\/guidance\/CG122\/chapter\/introduction."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2013.00256","article-title":"Getting to know ovarian cancer ascites: Opportunities for targeted therapy-based translational research","volume":"3","author":"Ahmed","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_91","unstructured":"Cancer Research UK Coping with Cancer\u2014Treating Fluid in the Abdomen. Available online: http:\/\/www.cancerresearchuk.org\/about-cancer\/coping-with-cancer\/coping-physically\/fluid-in-the-abdomen-ascites\/treating-fluid-in-abdomen#drain."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1089\/10430340260185139","article-title":"Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy","volume":"13","author":"Hemminki","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.gt.3301152","article-title":"Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients","volume":"7","author":"Stallwood","year":"2000","journal-title":"Gene Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1089\/10430340050111313","article-title":"Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid","volume":"11","author":"Blackwell","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/nprot.2006.328","article-title":"Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients","volume":"1","author":"Shepherd","year":"2007","journal-title":"Nat. Protoc."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/978-1-62703-547-7_24","article-title":"Establishment of primary cultures from ovarian tumor tissue and ascites fluid","volume":"1049","author":"Portelance","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e90604","DOI":"10.1371\/journal.pone.0090604","article-title":"The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis","volume":"9","author":"McCormick","year":"2014","journal-title":"PLoS ONE"},{"key":"ref_98","first-page":"1161","article-title":"Adenoviral gene therapy for cancer: From vectors to targeted and replication competent agents","volume":"21","author":"Bauerschmitz","year":"2002","journal-title":"Int. J. Oncol."},{"key":"ref_99","first-page":"798","article-title":"A phase I study of ONYX-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer","volume":"6","author":"Ganly","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/nm1095-1029","article-title":"Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy","volume":"1","author":"Bergh","year":"1995","journal-title":"Nat. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.2696","article-title":"Driver mutations in Tp53 are ubiquitous in high grade serous carcinoma of the ovary","volume":"221","author":"Ahmed","year":"2010","journal-title":"J. Pathol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609\u2013615.","DOI":"10.1038\/nature10166"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1126\/science.274.5293.1672","article-title":"Cancer cell cycles","volume":"274","author":"Sherr","year":"1996","journal-title":"Science"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/sj.mt.6300239","article-title":"Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRb pathway","volume":"15","author":"Cascallo","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-09-3167","article-title":"Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors","volume":"16","author":"Nokisalmi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/sj.onc.1206464","article-title":"A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy","volume":"22","author":"Post","year":"2003","journal-title":"Oncogene"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/hum.2013.229","article-title":"ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models","volume":"25","author":"Dong","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"8928","DOI":"10.1158\/0008-5472.CAN-08-1145","article-title":"Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency","volume":"68","author":"Gros","year":"2008","journal-title":"Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Vassilev, L., Ranki, T., Joensuu, T., Jager, E., Karbach, J., Wahle, C., Partanen, K., Kairemo, K., Alanko, T., and Turkki, R. (2015). Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8 T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer. Oncoimmunology, 4.","DOI":"10.1080\/2162402X.2015.1017702"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-12-2546","article-title":"Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus","volume":"19","author":"Kanerva","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"7855","DOI":"10.1038\/sj.onc.1204862","article-title":"The role of adenovirus E4orf4 protein in viral replication and cell killing","volume":"20","author":"Branton","year":"2001","journal-title":"Oncogene"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e2409","DOI":"10.1371\/journal.pone.0002409","article-title":"Directed evolution generates a novel oncolytic virus for the treatment of colon cancer","volume":"3","author":"Kuhn","year":"2008","journal-title":"PLoS ONE"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/gt.2014.2","article-title":"Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood","volume":"21","author":"Di","year":"2014","journal-title":"Gene Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ijc.25948","article-title":"Combining conditionally replicating adenovirus-mediated gene therapy with chemotherapy: A novel antitumor approach","volume":"129","author":"Jiang","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1158\/1078-0432.CCR-0349-03","article-title":"Use of replicating oncolytic adenoviruses in combination therapy for cancer","volume":"10","author":"Chu","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/ijc.28450","article-title":"Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites","volume":"134","author":"Jennings","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_119","first-page":"325","article-title":"Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy","volume":"59","author":"Li","year":"1999","journal-title":"Cancer Res."},{"key":"ref_120","first-page":"1057","article-title":"Coxsackie adenovirus receptor expression in carcinomas of the head and neck","volume":"32","author":"Wunder","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.molmed.2012.04.008","article-title":"Virus chimeras for gene therapy, vaccination, and oncolysis: Adenoviruses and beyond","volume":"18","author":"Kaufmann","year":"2012","journal-title":"Trends Mol. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1016\/j.vaccine.2004.02.011","article-title":"An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity","volume":"22","author":"Ophorst","year":"2004","journal-title":"Vaccine"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1128\/JVI.02058-12","article-title":"Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors","volume":"87","author":"Provine","year":"2013","journal-title":"J. Virol."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Uchino, J., Curiel, D.T., and Ugai, H. (2014). Species D human adenovirus type 9 exhibits better virus-spread ability for antitumor efficacy among alternative serotypes. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087342"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"9590","DOI":"10.1128\/JVI.00740-12","article-title":"Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys","volume":"86","author":"Teigler","year":"2012","journal-title":"J. Virol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1089\/hum.2013.215","article-title":"CD46-mediated transduction of a species D adenovirus vaccine improves mucosal vaccine efficacy","volume":"25","author":"Camacho","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1099\/vir.0.008342-0","article-title":"Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN","volume":"90","author":"Adams","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"6712","DOI":"10.1158\/1078-0432.CCR-11-0968","article-title":"Species D adenoviruses as oncolytics against B-cell cancers","volume":"17","author":"Chen","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/hum.1996.7.1-79","article-title":"\u201cSero-switch\u201d Adenovirus-mediated in vivo gene transfer: Circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype","volume":"7","author":"Mastrangeli","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/hum.1997.8.1-99","article-title":"Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype","volume":"8","author":"Mack","year":"1997","journal-title":"Hum. Gene Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/mt.2012.162","article-title":"Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery","volume":"20","author":"Coughlan","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1128\/CVI.00207-14","article-title":"Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors","volume":"21","author":"Teigler","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"11627","DOI":"10.1128\/JVI.79.18.11627-11637.2005","article-title":"Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation","volume":"79","author":"Schoggins","year":"2005","journal-title":"J. Virol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/gt.2010.37","article-title":"Influence of chimeric human-bovine fibers on adenoviral uptake by liver cells and the antiviral immune response","volume":"17","author":"Rogee","year":"2010","journal-title":"Gene Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1089\/hum.2004.15.1054","article-title":"Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo","volume":"15","author":"Denby","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1749-8090-8-183","article-title":"Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile","volume":"8","author":"White","year":"2013","journal-title":"J. Cardiothorac. Surg."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2009-12-260026","article-title":"Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors","volume":"116","author":"Alba","year":"2010","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/gt.2013.44","article-title":"Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction","volume":"20","author":"Parker","year":"2013","journal-title":"Gene Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2013.228","article-title":"Circumventing antivector immunity: Potential use of nonhuman adenoviral vectors","volume":"25","author":"Podgorski","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.coph.2015.08.004","article-title":"CAV-2\u2014Why a canine virus is a neurobiologist\u2019s best friend","volume":"24","author":"Junyent","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"6930","DOI":"10.1128\/JVI.73.8.6930-6936.1999","article-title":"Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo","volume":"73","author":"Hofmann","year":"1999","journal-title":"J. Virol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.virusres.2004.05.003","article-title":"Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture","volume":"105","author":"Bangari","year":"2004","journal-title":"Virus Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1006\/viro.2000.0350","article-title":"Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: Implications in gene therapy","volume":"272","author":"Moffatt","year":"2000","journal-title":"Virology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.virol.2004.03.028","article-title":"An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism","volume":"324","author":"Glasgow","year":"2004","journal-title":"Virology"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3390\/v6041540","article-title":"Peptide-based technologies to alter adenoviral vector tropism: Ways and means for systemic treatment of cancer","volume":"6","author":"Reetz","year":"2014","journal-title":"Viruses"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1089\/hum.2015.015","article-title":"Incorporation of peptides targeting EGFR and FGFR1 into the adenoviral fiber knob domain and their evaluation as targeted cancer therapies","volume":"26","author":"Legut","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1128\/JVI.75.16.7280-7289.2001","article-title":"Genetic retargeting of adenovirus: Novel strategy employing \u201cdeknobbing\u201d of the fiber","volume":"75","author":"Magnusson","year":"2001","journal-title":"J. Virol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1128\/JVI.01896-07","article-title":"Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer","volume":"82","author":"Belousova","year":"2008","journal-title":"J. Virol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"11309","DOI":"10.1158\/0008-5472.CAN-07-0739","article-title":"An oncolytic adenovirus redirected with a tumor-specific T-cell receptor","volume":"67","author":"Sebestyen","year":"2007","journal-title":"Cancer Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world\u2019s first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/156800907780058817","article-title":"Clinical trials with oncolytic adenovirus in China","volume":"7","author":"Yu","year":"2007","journal-title":"Curr. Cancer Drug Targrts"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/sj.gt.3301424","article-title":"Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity","volume":"8","author":"Nemunaitis","year":"2001","journal-title":"Gene Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/sj.cgt.7700539","article-title":"Intravascular adenoviral agents in cancer patients: Lessons from clinical trials","volume":"9","author":"Reid","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymthe.2006.02.011","article-title":"A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer","volume":"14","author":"Small","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0090-4295(02)01748-X","article-title":"Integrin \u03b1 v and coxsackie adenovirus receptor expression in clinical bladder cancer","volume":"60","author":"Sachs","year":"2002","journal-title":"Urology"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/sj.cgt.7700284","article-title":"Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression","volume":"8","author":"You","year":"2001","journal-title":"Cancer Gene Ther."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/S0959-8049(02)00131-4","article-title":"The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells","volume":"38","author":"Kim","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1006\/gyno.2002.6607","article-title":"Enhancement of the adenoviral sensitivity of human ovarian cancer cells by transient expression of coxsackievirus and adenovirus receptor (CAR)","volume":"85","author":"Kim","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejpb.2013.07.002","article-title":"Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: A review","volume":"85","author":"Hadinoto","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1089\/10430349950018021","article-title":"PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo","volume":"10","author":"Lachapelle","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.gt.3300665","article-title":"Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro","volume":"5","author":"Lee","year":"1998","journal-title":"Gene Ther."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1248\/bpb.27.936","article-title":"Neutralizing antibody evasion ability of adenovirus vector induced by the bioconjugation of methoxypolyethylene glycol succinimidyl propionate (mPEG-SPA)","volume":"27","author":"Eto","year":"2004","journal-title":"Biol. Pharm. Bull."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1248\/bpb.33.1540","article-title":"Optimized PEGylated adenovirus vector reduces the anti-vector humoral immune response against adenovirus and induces a therapeutic effect against metastatic lung cancer","volume":"33","author":"Eto","year":"2010","journal-title":"Biol. Pharm. Bull."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1016\/j.biomaterials.2012.02.011","article-title":"A hexon-specific pegylated adenovirus vector utilizing blood coagulation factor X","volume":"33","author":"Matsui","year":"2012","journal-title":"Biomaterials"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.mt.6300321","article-title":"Modification of adenovirus gene transfer vectors with synthetic polymers: A scientific review and technical guide","volume":"16","author":"Kreppel","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.biomaterials.2010.10.060","article-title":"Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction","volume":"32","author":"Katayama","year":"2011","journal-title":"Biomaterials"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/mt.2010.229","article-title":"Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells","volume":"19","author":"Prill","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1089\/hum.2009.028","article-title":"Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus","volume":"20","author":"Doronin","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jconrel.2014.04.012","article-title":"Bioreducible polymers for therapeutic gene delivery","volume":"190","author":"Lee","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.biomaterials.2009.11.043","article-title":"The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy","volume":"31","author":"Kim","year":"2010","journal-title":"Biomaterials"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1021\/bm501116x","article-title":"Safety profiles and antitumor efficacy of oncolytic adenovirus coated with bioreducible polymer in the treatment of a CAR-negative tumor model","volume":"16","author":"Jung","year":"2015","journal-title":"Biomacromolecules"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1021\/acs.bioconjchem.5b00357","article-title":"Tuning surface charge and PEGylation of biocompatible polymers for efficient delivery of nucleic acid or adenoviral vector","volume":"26","author":"Choi","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e82716","DOI":"10.1371\/journal.pone.0082716","article-title":"Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivo","volume":"9","author":"Prill","year":"2014","journal-title":"PLoS ONE"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.gt.3301389","article-title":"Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies","volume":"8","author":"Fisher","year":"2001","journal-title":"Gene Ther."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/10611860400020449","article-title":"Enhanced gene transfer activity of peptide-targeted gene-delivery vectors","volume":"13","author":"Parker","year":"2005","journal-title":"J. Drug Target."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1016\/j.biomaterials.2011.03.084","article-title":"Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA","volume":"32","author":"Kim","year":"2011","journal-title":"Biomaterials"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijpharm.2014.08.024","article-title":"Formulation and in vitro and in vivo evaluation of a cationic emulsion as a vehicle for improving adenoviral gene transfer","volume":"475","author":"Kim","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1517\/17425247.2012.739603","article-title":"Ultrasound-enhanced drug delivery for cancer","volume":"9","author":"Mo","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/jnci\/djt305","article-title":"Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound","volume":"105","author":"Carlisle","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2015.05.265","article-title":"Increasing the density of nanomedicines improves their ultrasound-mediated delivery to tumours","volume":"210","author":"Mo","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/8647","article-title":"A system for the propagation of adenoviral vectors with genetically modified receptor specificities","volume":"17","author":"Douglas","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"ref_182","first-page":"265","article-title":"Endothelial cell vehicles for delivery of cytotoxic genes as a gene therapy approach for carcinoma of the ovary","volume":"4","author":"Rancourt","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1128\/JVI.74.15.6875-6884.2000","article-title":"Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells","volume":"74","author":"Dmitriev","year":"2000","journal-title":"J. Virol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/sj.gt.3302103","article-title":"Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors","volume":"10","author":"Mastenbroek","year":"2003","journal-title":"Gene Ther."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1089\/hum.2009.190","article-title":"Targeting adenoviruses with factor X-single-chain antibody fusion proteins","volume":"21","author":"Chen","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1006\/mthe.2001.0342","article-title":"Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105)","volume":"3","author":"Nettelbeck","year":"2001","journal-title":"Mol. Ther."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.virol.2006.11.011","article-title":"A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor","volume":"361","author":"Carette","year":"2007","journal-title":"Virology"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jmb.2010.10.040","article-title":"Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting","volume":"405","author":"Dreier","year":"2011","journal-title":"J. Mol. Biol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"E869","DOI":"10.1073\/pnas.1213653110","article-title":"Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric darpin adapters","volume":"110","author":"Dreier","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/gt.2010.45","article-title":"Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor","volume":"17","author":"Harvey","year":"2010","journal-title":"Gene Ther."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_192","unstructured":"Zarour, H., DeLeo, A., Finn, O., and Storkus, W. (2003). Categories of Tumor Antigens, BC Decker. [6th ed.]."},{"key":"ref_193","first-page":"4481","article-title":"Novel treatment strategies for cancer and their tumor-targeting approaches using antibodies against tumor-associated antigens","volume":"34","author":"Kuroki","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"15101","DOI":"10.1073\/pnas.2135379100","article-title":"An adenoviral vector cancer vaccine that delivers a tumor-associated antigen\/CD40-ligand fusion protein to dendritic cells","volume":"100","author":"Zhang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/hum.2013.235","article-title":"Adenovirus-based vaccines for fighting infectious diseases and cancer: Progress in the field","volume":"25","author":"Majhen","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Woller, N., G\u00fcrlevik, E., Ureche, C.I., Schumacher, A., and K\u00fchnel, F. (2014). Oncolytic viruses as anticancer vaccines. Front. Oncol., 4.","DOI":"10.3389\/fonc.2014.00188"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(08)70107-4","article-title":"Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A phase I trial","volume":"9","author":"Park","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2217\/fon.10.66","article-title":"Optim trial: A phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma","volume":"6","author":"Kaufman","year":"2010","journal-title":"Future Oncol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nbt0613-471","article-title":"Amgen announces oncolytic virus shrinks tumors","volume":"31","author":"Sheridan","year":"2013","journal-title":"Nat. Biotech."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"P263","DOI":"10.1186\/2051-1426-2-S3-P263","article-title":"Final planned overall survival (OS) from Optim, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB\/C\/IV melanoma (nct00769704)","volume":"2","author":"Andtbacka","year":"2014","journal-title":"J. Immunother. Cancer"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00262-012-1319-0","article-title":"Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma","volume":"62","author":"Phuphanich","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/CVI.00286-10","article-title":"Translating tumor antigens into cancer vaccines","volume":"18","author":"Buonaguro","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Nguyen, A., Ho, L., and Wan, Y. (2014). Chemotherapy and oncolytic virotherapy: Advanced tactics in the war against cancer. Front. Oncol., 4.","DOI":"10.3389\/fonc.2014.00145"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/mt.2010.98","article-title":"Potentiating cancer immunotherapy using an oncolytic virus","volume":"18","author":"Bridle","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"e0125851","DOI":"10.1371\/journal.pone.0125851","article-title":"Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: Implications for immune-mediated cancer therapy","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS ONE"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cellimm.2015.06.003","article-title":"In vitro antitumor immune response induced by dendritic cells transduced with human livin alpha recombinant adenovirus","volume":"297","author":"Xie","year":"2015","journal-title":"Cell Immunol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fimmu.2014.00074","article-title":"Armed therapeutic viruses\u2014A disruptive therapy on the horizon of cancer immunotherapy","volume":"5","author":"Bauzon","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","article-title":"CTLA-4 and PD-1\/PD-L1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients","volume":"19","author":"Ott","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: From discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int. Immunol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1189\/jlb.1212631","article-title":"At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy","volume":"94","author":"Callahan","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4049\/jimmunol.177.2.1052","article-title":"CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism","volume":"177","author":"Engelhardt","year":"2006","journal-title":"J. Immunol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1593\/neo.05733","article-title":"The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors","volume":"8","author":"Ghebeh","year":"2006","journal-title":"Neoplasia"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/gt.2011.176","article-title":"Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4","volume":"19","author":"Dias","year":"2012","journal-title":"Gene Ther."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/mt.2014.160","article-title":"CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy","volume":"22","author":"Engeland","year":"2014","journal-title":"Mol. Ther."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/7\/11\/2923\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:52:38Z","timestamp":1760215958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/7\/11\/2923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,24]]},"references-count":219,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,11]]}},"alternative-id":["v7112923"],"URL":"https:\/\/doi.org\/10.3390\/v7112923","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,24]]}}}